SUBSCRIBE
SUBSCRIBE
News   Policy

GlaxoSmithKline, Human Genome Sciences, Inc. Get Fast Review For Lupus Drug

August 19, 2010 | 
1 min read
LONDON, Aug 19 (Reuters) - A keenly awaited new lupus drug from GlaxoSmithKline Plc (GSK.L) and Human Genome Sciences Inc (HGSI.O) will get a priority review from U.S. regulators, potentially clearing the way for its approval by mid-December.
Regulatory Europe
GlaxoSmithKline
MORE ON THIS TOPIC
Contemporary art collage. Giang hand kicking office worker symbolizing dismissal. Unsuccessful employee. Job reduction. Concept of business, career, failure, success, troubles
Rare diseases
Ultragenyx Takes Second Hit as FDA Rejects Gene Therapy for Sanfilippo Syndrome
July 14, 2025
 · 
2 min read
 · 
Tristan Manalac
Regulatory
FDA Mulls Speedier Reviews to Companies Willing To Lower Drug Costs
July 14, 2025
 · 
1 min read
 · 
Tristan Manalac
Contemporary art collage showing a hand giving a thumbs down surrounded by red arrows pointing down, concept of negative feedback and bad review
Complete response letters
Capricor Plunges on FDA Rejection of DMD Cell Therapy
July 11, 2025
 · 
3 min read
 · 
Tristan Manalac
Person buried in paperwork hand raised collage art. Man drown in work concept. Overwork illustration for news banner, web articles, and posters
FDA
FDA Rejections: We Read 200 CRLs So You Don’t Have To
July 11, 2025
 · 
5 min read
 · 
Annalee Armstrong